Trump announces efforts to expand access to IVF drugs

Trump announces efforts to expand access to IVF drugs


U.S. President Donald Trump delivers remarks before signing an executive order on expanding access to IVF at his Mar-a-Lago resort on Feb. 18, 2025 in Palm Beach, Florida.

Joe Raedle | Getty Images

President Donald Trump on Thursday announced two new efforts to expand the availability of in vitro fertilization, the first concrete step from his administration on the expensive and politically fraught procedure.

Trump struck a deal with EMD Serono, a subsidiary of Germany’s Merck KGaA, to slash the price of some of the company’s fertility medicines in exchange for relief from planned tariffs on pharmaceuticals imported into the U.S., which Trump has not yet imposed.

The Trump administration will also be issuing guidance encouraging employers to offer fertility benefits directly to their employees, which would work similarly to vision or dental coverage. It will allow employers to offer add-on coverage at a fixed cost for patients and employers. But it’s unclear how much the effort will increase coverage, as it does not mandate that employers participate.

At a press conference Thursday, Trump said the moves will lead to “many more beautiful American children.”

“We’ll dramatically slash the cost of IVF and the treatment and many of the most common fertility drugs for countless millions of Americans,” Trump said. “Prices are going way down, way, way down.”

EMD Serono, the largest fertility drug manufacturer in the world, said it will sell its IVF therapies directly to patients and that people will be able to buy the drugs on Trump’s direct-to-consumer purchasing site, TrumpRx.gov. That site will launch in January 2026.

The medications include Gonal-f, a critical drug used in the shot protocol required for egg stimulation.

The plan comes as Trump works to rein in prescription drug costs in the U.S., inking deals with Pfizer and AstraZeneca in recent weeks that aim to make it easier for Americans to access certain drugs.

Millions of babies have been born through IVF, which involves combining eggs and sperm in a laboratory to create an embryo for couples having difficulty conceiving. The decades-old procedure is an issue that the president repeatedly vowed to address on the campaign trail, calling himself the “father of IVF” last fall.

The procedure is often not fully covered by insurance — if at all — and it can cost around $20,000 or more per cycle. Only a quarter of companies with more than 200 employees currently cover IVF. Some studies have shown that an IVF cycle in the U.S. costs 271% more than the average in 25 other countries. 

Trump issued an executive order on IVF shortly after the president took office, promising to lower costs and make the procedure more accessible. But that order did not provide specifics apart from promising to put out a detailed report with recommendations on the issue by late May. That report has not been released. 

The procedure became a flashpoint in the nationwide clash over abortion and reproductive rights in early 2024 when Alabama’s Supreme Court said that frozen embryos are children and those who destroy them can be held liable for wrongful death. In some cases, embryos may be discarded during IVF. 

Trump quickly distanced himself from that ruling last year, urging the Alabama Legislature to protect access to IVF. 

Americans generally support the procedure. An April 2024 poll from Pew Research Center found that seven in 10 U.S. adults say IVF access is a good thing, with modest differences across most demographic and partisan groups. 



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More